Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey
Makaleler > Tam Makale · 2012
Yazarlar: Ziver Sahin, Muge Bicakcigil, Kenan AKSU, Sevil Kamali, Servet Akar, Fatos Onen, ÖMER KARADAĞ, Zeynep OZBALKAN, Askin ATES, HÜSEYİN TURGUT ELBEK ÖZER, Vuslat Yilmaz, Emire Seyahi, Mehmet A. Ozturk, Ayse Cefle, Veli Cobankara, A. Mesut Onat, Ercan Tunc, Nursen Duzgun, Sibel Z. Aydin, Neslihan Yilmaz, Izzet Fresko, Yasar KARAASLAN, Sedat Kiraz, Nurullah Akkoc, Murat Inanc, Gökhan KESER, F. Aytul Uyar, Suzan GÜVEN, Guher Saruhan-Direskeneli
Arthritis Research & Therapy, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2012, cilt 14, ss R27-R27
DOI: 10.1186/ar3730
Özet
INTRODUCTION: HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical and immunological differences. In this study, we aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as susceptibility and severity factors. METHODS: TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n = 210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-specific primers. RESULTS: We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR = 0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P = 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs 26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78). CONCLUSIONS: In this study, the previously reported association of TAK with HLA-B*52 in other populations was confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored further.